The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity Nature| https://doi.org/10.1038/s41586-023-06575-7
AbbVie authors: Christina K. Baumgartner, Jennifer M. Frost, Philip R. Kym, Keith M. Hamel, Kathleen A. McGuire, Geoff T. Halvorsen, Prasanthi Geda, Kelly L. Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Domenick E. Kennedy, Angeline Chen, Kenton Longenecker, Joseph T. Klahn, Cara L. Hrusch, Navasona Krishnan, Charles W. Hutchins, Jacqueline D. Aguado, Marinka Bulic, Joshua H. Decker, Yi Yang, Magali Guffroy, Stacey Fossey, Patricia Trusk, Wei Qiu, Qi Sun
Importance of PLD2 in an IL-23 driven psoriasiform dermatitis model and potential link to human psoriasis The Journal of Dermatology | https://doi.org/10.1111/1346-8138.16899
AbbVie authors: Zhi Su, Peter Slivka, Stephanie Paulsboe, Katherine Chu, Joseph B. Wetter, Marian Namovic, Denise Perron, Arun Kannan, Qi Wan, Charlene Manning, Viktor Todorovic, Kathleen M. Smith, Alex Lipovsky, Yibing Wang, Kristine Frank, Steve McGaraughty, Jacqueline Loud, Victoria E. Scott, Prisca Honore and Eric R. Goedken
Proof-of-Concept in Developing a 45% Drug Loaded Amorphous Nanoparticle Formulation Journal of Pharmaceutical Sciences | https://doi.org/10.1016/j.xphs.2023.10.012
AbbVie authors: Hitesh Purohit, Deliang Zhou, Mengqi Yu, Maryam Zaroudi, Hardeep Oberoi, Angélica de L.Rodríguez López, Manish S. Kelkar, Yan He, Bradley Gates, Nandkishor Nere and Devalina Law
Clinical Bridging From Prefilled Syringe to On-Body Injector for Risankizumab in Crohn's Disease Clinical Therapeutics | https://doi.org/10.1016/j.clinthera.2023.10.008
AbbVie authors: Yinuo Pang, Ronilda D'Cunha, Afroz Shareef Mohammad, Rachel Duan, Jasmina Kalabic, Toni Anschutz, Sai Nudurupati, Kori Wallace, Manuela Jaeschke, Sujani Nannapaneni, Ji Zhou, Wei Liu and Patrick Marroum